Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging

Gormley, Thomas S.; Every, Marvin J. Van; Moreno, Albert J.

doi:10.1016/s0090-4295(96)00095-7

Cited by 42 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether some aspect of an oncocytoma that would cause it to grow to a large size or develop a central scar would also lead to increased 99m Tc-MIBI uptake will require further investigation. Of note, the 99m Tc-MIBI–avid oncocytoma reported by Gormley et al 9 was also quite large.…”

Section: Discussionmentioning

confidence: 83%

“…To this end, the authors studied 6 patients with renal tumors (1 oncocytoma, 1 angiomyolipoma, 1 simple cyst, and 3 RCCs) using planar 99m Tc-MIBI imaging. 9 Compared with the adjacent normal renal parenchyma, the 1 oncocytoma showed a 1.44-fold increase in MIBI uptake. In contrast, the 5 other lesions appeared photopenic (range of uptake ratios, 0.55–0.86).…”

mentioning

confidence: 90%

“…7,8 Taking advantage of this property, Gormley and coworkers 9 tested whether oncocytomas could be differentiated from other renal tumors using the mitochondrial imaging agent 99m Tc-MIBI. To this end, the authors studied 6 patients with renal tumors (1 oncocytoma, 1 angiomyolipoma, 1 simple cyst, and 3 RCCs) using planar 99m Tc-MIBI imaging.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Initial Experience Using 99mTc-MIBI SPECT/CT for the Differentiation of Oncocytoma From Renal Cell Carcinoma

Rowe¹,

Gorin²,

Gordetsky³

et al. 2015

Clinical Nuclear Medicine

View full text Add to dashboard Cite

PurposeThe differentiation of oncocytoma from renal cell carcinoma (RCC) remains a challenge with currently available cross-sectional imaging techniques. As a result, a large number of patients harboring a benign oncocytoma undergo unnecessary surgical resection. In this study, we explored the utility of 99mTc-MIBI SPECT/CT for the differentiation of these tumors based on the hypothesis that the large number of mitochondria in oncocytomas would lead to increased 99mTc-MIBI uptake.Patients and MethodsIn total, 6 patients (3 with oncocytoma and 3 with RCC) were imaged with 99mTc-MIBI SPECT/CT. Relative quantification was performed by measuring tumor-to-normal renal parenchyma background ratios.ResultsAll 3 oncocytomas demonstrated radiotracer uptake near or above the normal renal parenchymal uptake (range of uptake ratios, 0.85–1.78). In contrast, the 3 RCCs were profoundly photopenic relative to renal background (range of uptake ratios, 0.21–0.31).Conclusions99mTc-MIBI SPECT/CT appears to be of value in scintigraphically distinguishing benign renal oncocytoma from RCC.

show abstract

Section: Discussionmentioning

confidence: 83%

mentioning

confidence: 90%

See 1 more Smart Citation

Initial Experience Using 99mTc-MIBI SPECT/CT for the Differentiation of Oncocytoma From Renal Cell Carcinoma

Rowe¹,

Gorin²,

Gordetsky³

et al. 2015

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…51 our team conducted a pilot study of 99m Tcsestamibi imaging of three biopsy-proven oncocytomas as well as three surgically resected RCCs using modern 99m Tc-sestamibi SPECT/CT. 52 In line with the original findings of Gormely, 51 we observed that the three imaged oncocytomas accumulated 99m Tc-sestamibi at or near the renal background level, whereas the three imaged RCCs, including one ccRCC, one translocation RCC and one unclassified RCC, each appeared as marked photopenic defects (Figure 3). Combined, these two studies provide preliminary evidence that 99m Tc-sestamibi imaging could be a useful nuclear imaging technique for distinguishing renal oncocytomas from other indeterminate renal masses.…”

Section: Zr-bevacizumabmentioning

confidence: 99%

Nuclear imaging of renal tumours: a step towards improved risk stratification

2015

View full text Add to dashboard Cite

Patients presenting with a clinically localized renal mass should ideally be managed with a risk-adapted approach that incorporates data regarding the metastatic potential of a given tumour. Unfortunately, currently available anatomical imaging techniques are unable to reliably distinguish between the various types of renal tumours, which include both benign and malignant histologies. Nuclear imaging offers a potential noninvasive means to characterize clinically localized renal tumours. A number of nuclear imaging tests are currently under investigation for this purpose and might one day be incorporated into patient care.

show abstract

“…The biologic rationale for nuclear scanning is therefore strong, but these results have not been confirmed, and their clinical role or utility has not been developed. [170] As aforementioned, ultrasonography, computerized tomography, and magnetic resonance imaging are all commonly used in the evaluation and diagnosis of renal masses. However, a common criticism is that they mostly provide a morphometric analysis, are indeed sensitive, but not very specific.…”

Section: Nuclear Imaging and Differentiation Of Renal Massesmentioning

confidence: 99%